Baidu
map

感染

订阅

MedSci主页 / 所有栏目 / 感染

JCLA：肿瘤坏死因子的功能性变体β基因在颞下颌紊乱的影响量

2019-06-01 不详 网络

肿瘤坏死因子功能
关注

颞下颌关节紊乱症(TMD)是一组引起慢性口腔颌面部疼痛的疾病。肿瘤坏死因子β(TNFβ)是一种促炎细胞因子，参与炎症过程包括组织和维护的各个方面，以及在炎症细胞的排列。本研究的目的是在土耳其的队中列评估肿瘤坏死因子检测β+ 252 a / G (rs909253)变体和易感性之间的相关性。

颞下颌关节紊乱症(TMD)是一组引起慢性口腔颌面部疼痛的疾病。肿瘤坏死因子β(TNFβ)是一种促炎细胞因子，参与炎症过程包括组织和维护的各个方面，以及在炎症细胞的排列。本研究的目的是在土耳其的队中列评估肿瘤坏死因子检测β+ 252 a / G (rs909253)变体和易感性之间的相关性。

研究包括104例TMD患者(26名男性，78名女性)和126名健康对照组(44名男性，82名女性)。肿瘤坏死因子检测β+ 252 a / G变异分析基于聚合酶链反应检测限制片段长度多态性(PCR RFLP)。

研究发信啊，在病人和对照组没有偏离TNFβ+ 252A/G变体。患者组和对照组的肿瘤坏死因子β+ 252 / G变体之间分别有显著差异基因型和等位基因频率 (P = 0.010, 0.015)。与健康对照组相比，发现TMD患者一个显著增加肿瘤坏死因子β+ 252 AG基因型和G等位基因频率。具有GG基因型和G等位基因的个体发生TMD的风险增加。当按AA基因型与AG+GG基因型与对照组比较时，观察到有统计学意义的相关性(P = 0.002，或:2.23,95% CI:1.31‐3.82)。肿瘤坏死因子β+ 252 A/G 基因型分布与咀嚼问题(P = 0.046)。

总之，我们的研究结果提供的证据表明，肿瘤坏死因子量β252 A/G变异可能导致土耳其研究队列中TMD的发展。需要进一步的研究来证实这一观察结果。

原始出处：

Kaan Yerliyurt, Ayse Feyda Nursal ,Effect of a functional variant of tumor necrosis factor‐β gene in temporomandibular disorders: A pilot study

本文系梅斯医学（MedSci）原创编译整理，转载需授权！


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1915507, encodeId=a88c191550e57, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Mon Feb 10 08:51:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037626, encodeId=e2b4203e62647, content=<a href='/topic/show?id=75c1100e6852' target=_blank style='color:#2F92EE;'>#颞下颌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100768, encryptionId=75c1100e6852, topicName=颞下颌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Sun Jul 07 08:51:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633121, encodeId=25d4163312104, content=<a href='/topic/show?id=c8a6100e6793' target=_blank style='color:#2F92EE;'>#颞下#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100767, encryptionId=c8a6100e6793, topicName=颞下)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbe822016862, createdName=fengyi819, createdTime=Fri Dec 06 22:51:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699772, encodeId=bfd11699e72b7, content=<a href='/topic/show?id=dd152024130' target=_blank style='color:#2F92EE;'>#下颌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20241, encryptionId=dd152024130, topicName=下颌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4f29973299, createdName=xlysu, createdTime=Wed Sep 11 13:51:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362948, encodeId=a8321362948ea, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Mon Jun 03 06:51:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485476, encodeId=591514854e655, content=<a href='/topic/show?id=3879828e19d' target=_blank style='color:#2F92EE;'>#肿瘤坏死因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82871, encryptionId=3879828e19d, topicName=肿瘤坏死因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43077999209, createdName=ms7524819409032184, createdTime=Mon Jun 03 06:51:00 CST 2019, time=2019-06-03, status=1, ipAttribution=)]
    2020-02-10 xlxchina

    #功能性#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1915507, encodeId=a88c191550e57, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Mon Feb 10 08:51:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037626, encodeId=e2b4203e62647, content=<a href='/topic/show?id=75c1100e6852' target=_blank style='color:#2F92EE;'>#颞下颌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100768, encryptionId=75c1100e6852, topicName=颞下颌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Sun Jul 07 08:51:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633121, encodeId=25d4163312104, content=<a href='/topic/show?id=c8a6100e6793' target=_blank style='color:#2F92EE;'>#颞下#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100767, encryptionId=c8a6100e6793, topicName=颞下)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbe822016862, createdName=fengyi819, createdTime=Fri Dec 06 22:51:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699772, encodeId=bfd11699e72b7, content=<a href='/topic/show?id=dd152024130' target=_blank style='color:#2F92EE;'>#下颌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20241, encryptionId=dd152024130, topicName=下颌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4f29973299, createdName=xlysu, createdTime=Wed Sep 11 13:51:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362948, encodeId=a8321362948ea, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Mon Jun 03 06:51:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485476, encodeId=591514854e655, content=<a href='/topic/show?id=3879828e19d' target=_blank style='color:#2F92EE;'>#肿瘤坏死因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82871, encryptionId=3879828e19d, topicName=肿瘤坏死因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43077999209, createdName=ms7524819409032184, createdTime=Mon Jun 03 06:51:00 CST 2019, time=2019-06-03, status=1, ipAttribution=)]
    2019-07-07 12498761m56暂无昵称

    #颞下颌#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1915507, encodeId=a88c191550e57, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Mon Feb 10 08:51:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037626, encodeId=e2b4203e62647, content=<a href='/topic/show?id=75c1100e6852' target=_blank style='color:#2F92EE;'>#颞下颌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100768, encryptionId=75c1100e6852, topicName=颞下颌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Sun Jul 07 08:51:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633121, encodeId=25d4163312104, content=<a href='/topic/show?id=c8a6100e6793' target=_blank style='color:#2F92EE;'>#颞下#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100767, encryptionId=c8a6100e6793, topicName=颞下)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbe822016862, createdName=fengyi819, createdTime=Fri Dec 06 22:51:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699772, encodeId=bfd11699e72b7, content=<a href='/topic/show?id=dd152024130' target=_blank style='color:#2F92EE;'>#下颌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20241, encryptionId=dd152024130, topicName=下颌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4f29973299, createdName=xlysu, createdTime=Wed Sep 11 13:51:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362948, encodeId=a8321362948ea, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Mon Jun 03 06:51:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485476, encodeId=591514854e655, content=<a href='/topic/show?id=3879828e19d' target=_blank style='color:#2F92EE;'>#肿瘤坏死因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82871, encryptionId=3879828e19d, topicName=肿瘤坏死因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43077999209, createdName=ms7524819409032184, createdTime=Mon Jun 03 06:51:00 CST 2019, time=2019-06-03, status=1, ipAttribution=)]
    2019-12-06 fengyi819

    #颞下#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1915507, encodeId=a88c191550e57, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Mon Feb 10 08:51:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037626, encodeId=e2b4203e62647, content=<a href='/topic/show?id=75c1100e6852' target=_blank style='color:#2F92EE;'>#颞下颌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100768, encryptionId=75c1100e6852, topicName=颞下颌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Sun Jul 07 08:51:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633121, encodeId=25d4163312104, content=<a href='/topic/show?id=c8a6100e6793' target=_blank style='color:#2F92EE;'>#颞下#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100767, encryptionId=c8a6100e6793, topicName=颞下)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbe822016862, createdName=fengyi819, createdTime=Fri Dec 06 22:51:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699772, encodeId=bfd11699e72b7, content=<a href='/topic/show?id=dd152024130' target=_blank style='color:#2F92EE;'>#下颌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20241, encryptionId=dd152024130, topicName=下颌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4f29973299, createdName=xlysu, createdTime=Wed Sep 11 13:51:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362948, encodeId=a8321362948ea, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Mon Jun 03 06:51:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485476, encodeId=591514854e655, content=<a href='/topic/show?id=3879828e19d' target=_blank style='color:#2F92EE;'>#肿瘤坏死因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82871, encryptionId=3879828e19d, topicName=肿瘤坏死因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43077999209, createdName=ms7524819409032184, createdTime=Mon Jun 03 06:51:00 CST 2019, time=2019-06-03, status=1, ipAttribution=)]
    2019-09-11 xlysu

    #下颌#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1915507, encodeId=a88c191550e57, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Mon Feb 10 08:51:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037626, encodeId=e2b4203e62647, content=<a href='/topic/show?id=75c1100e6852' target=_blank style='color:#2F92EE;'>#颞下颌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100768, encryptionId=75c1100e6852, topicName=颞下颌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Sun Jul 07 08:51:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633121, encodeId=25d4163312104, content=<a href='/topic/show?id=c8a6100e6793' target=_blank style='color:#2F92EE;'>#颞下#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100767, encryptionId=c8a6100e6793, topicName=颞下)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbe822016862, createdName=fengyi819, createdTime=Fri Dec 06 22:51:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699772, encodeId=bfd11699e72b7, content=<a href='/topic/show?id=dd152024130' target=_blank style='color:#2F92EE;'>#下颌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20241, encryptionId=dd152024130, topicName=下颌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4f29973299, createdName=xlysu, createdTime=Wed Sep 11 13:51:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362948, encodeId=a8321362948ea, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Mon Jun 03 06:51:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485476, encodeId=591514854e655, content=<a href='/topic/show?id=3879828e19d' target=_blank style='color:#2F92EE;'>#肿瘤坏死因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82871, encryptionId=3879828e19d, topicName=肿瘤坏死因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43077999209, createdName=ms7524819409032184, createdTime=Mon Jun 03 06:51:00 CST 2019, time=2019-06-03, status=1, ipAttribution=)]
    2019-06-03 millore

    #坏死#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1915507, encodeId=a88c191550e57, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Mon Feb 10 08:51:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037626, encodeId=e2b4203e62647, content=<a href='/topic/show?id=75c1100e6852' target=_blank style='color:#2F92EE;'>#颞下颌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100768, encryptionId=75c1100e6852, topicName=颞下颌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Sun Jul 07 08:51:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633121, encodeId=25d4163312104, content=<a href='/topic/show?id=c8a6100e6793' target=_blank style='color:#2F92EE;'>#颞下#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100767, encryptionId=c8a6100e6793, topicName=颞下)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbe822016862, createdName=fengyi819, createdTime=Fri Dec 06 22:51:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699772, encodeId=bfd11699e72b7, content=<a href='/topic/show?id=dd152024130' target=_blank style='color:#2F92EE;'>#下颌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20241, encryptionId=dd152024130, topicName=下颌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4f29973299, createdName=xlysu, createdTime=Wed Sep 11 13:51:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362948, encodeId=a8321362948ea, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Mon Jun 03 06:51:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485476, encodeId=591514854e655, content=<a href='/topic/show?id=3879828e19d' target=_blank style='color:#2F92EE;'>#肿瘤坏死因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82871, encryptionId=3879828e19d, topicName=肿瘤坏死因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43077999209, createdName=ms7524819409032184, createdTime=Mon Jun 03 06:51:00 CST 2019, time=2019-06-03, status=1, ipAttribution=)]
    2019-06-03 ms7524819409032184

    #肿瘤坏死因子#

    0

相关资讯

TNF抑制剂预处理可改善癌症免疫治疗的疗效

发表在Nature杂志上的研究数据显示，通过肿瘤坏死因子α（TNF）抑制剂预处理后，可以改善免疫治疗的效果。

Plos One：1型糖尿病患者血清中肿瘤坏死因子α水平的变化

近期，一项发表在杂志Plos One上的研究旨在评估1型糖尿病（T1DM）患者的血清中肿瘤坏死因子-α（TNF-α）的变化情况。此项研究从PubMed、Cochrane图书馆、CNKI、万方和中国Cqvip数据库（1999年1月1日至2016年9月30日发表）中筛选了相关文献。对血清TNF-α水平进行了汇总分析，并与年龄、病程和种族关系进行亚组分析。此项荟萃分析共纳入23篇文章（1631例T1DM

JAMA：对TNFα抑制剂反应不足的类风湿性关节炎患者或可选择非TNF生物制剂

三分之一的类风湿关节炎患者对肿瘤坏死因子α（TNFα）抑制剂的反应不足，缺少关于如何选择下一步治疗的指导。本研究旨在对比此类患者中靶向非肿瘤坏死因子的生物性药物与二抗肿瘤坏死因子药物的疗效。此多中心、实用性、开放标签的随机临床试验为期52周，2009-2012年间共有300名类风湿性关节炎患者，持续性疾病活动且对抗TNF治疗反应不足。最后的随访日期是2013年8月。将患者1：1随机分组分别接受非肿

Cell子刊：揭示肿瘤坏死因子抵抗感染新机制

作为免疫系统的一种信使分子，肿瘤坏死因子（tumor necrosis factor, TNF）在触发慢性炎症性疾病中发挥着重要作用。由于这个原因，TNF抑制剂是治疗类风湿性关节炎患者和某些炎症性肠病患者的一种标准方法。然而，TNF也防止感染，这意味着抑制它能够导致潜伏性感染重新露面。 如今，在一项新的研究中，来自德国埃朗根-纽伦堡大学（Friedrich-Alexander-Univ

Nat Commun：打破认知！肿瘤坏死因子控制血压！

来自泰德•罗杰斯心脏研究中心的研究人员发现了肿瘤坏死因子（TNF）的一个令人惊讶的新作用：它是小血管功能的主要调节因子，而小血管的功能是血液的关键决定因素。这项研究近日发表在Nature Communications上。长期以来，TNF都被认为与炎症相关，这也就催生了治疗慢性炎症疾病（如类风湿性关节炎、牛皮癣、肠易激综合症等）的抗

Nature：一个大胆的想法，改善肿瘤联合免疫治疗疗效

西班牙纳瓦拉临床大学（Clinica Universidad de Navarra）的研究人员领导的一项合作性实验提出了一种治疗癌症的方法，将联合免疫疗法的疗效和毒性分离开来，其临床策略包括应用联合免疫治疗（PD-1和CTLA-4等“减缓”免疫反应的蛋白质），同时阻断参与免疫系统调节的蛋白质（肿瘤坏死因子，TNF）。国际领先的科学周刊《Nature》在最新一期刊登了这项研究。

Baidu
map
Baidu
map
Baidu
map